Skip to main content
Premium Trial:

Request an Annual Quote

Nuclea Biotech Mass Spec-Based Assays

Nuclea Biotechnologies said it will start offering more than 50 research-use-only mass spectrometry-based biomarker tests as part of its laboratory services. The tests are designed to detect and quantify key protein biomarkers in human serum or plasma and are available to pharmaceutical firms for clinical trials, to researchers, and as companion diagnostics. Nuclea recently established its first CLIA/CAP certified clinical service laboratory in Pittsfield, Massachusetts, where it offers an array of fully validated and reimbursable IHC and ELISA tests for cancer-associated proteins in tissue and blood. Nuclea will launch a second, high-complexity CLIA lab in its Cambridge, Massachusetts facility in late 2015. In addition to IHC and ELISA tests, this lab will offer mass spec-based multiplexed assays for serum or plasma proteins associated with diabetes, metabolic syndrome, and obesity.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.